DeepMed Research

Etoricoxib

Generic Name: Etoricoxib

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₅ClN_₂O_₂S

CAS Number: 202409-33-4

Unique Ingredient Identifier: WRX4NFY03R

Background: Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.

Indication: For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.

Associated Conditions: Ankylosing Spondylitis (AS), Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Moderate Pain

Clinical Trials

Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty

Phase 3

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Placebo
Drug: pregabalin
Drug: Etoricoxib
Drug: paracetamol
Drug: Morphine
Drug: Ropivacaine

First Posted Date: 2016-11-03

Last Posted Date: 2017-09-14

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 116

Registration Number: NCT02954484

Analgesia in Inguinal Hernia Repair Using a Cyclooxygenase-2-specific Inhibitor

Not Applicable

Completed

Conditions: Adverse Anesthesia Outcome

Interventions: Drug: Placebo
Drug: Etoricoxib

First Posted Date: 2016-08-31

Last Posted Date: 2016-08-31

Lead Sponsor: Bnai Zion Medical Center

Target Recruit Count: 60

Registration Number: NCT02884986

Locations: 🇮🇱
Bnai Zion Medical Center, Haifa, Israel

Lornoxicam Versus Etoricoxib in Postoperative Pain After Total Knee Arthroplasty

Phase 3

Completed

Conditions: Postoperative Pain

Interventions: Drug: Lornoxicam
Drug: Etoricoxib

First Posted Date: 2016-04-26

Last Posted Date: 2016-04-26

Lead Sponsor: Foisor Orthopedics Clinical Hospital

Target Recruit Count: 120

Registration Number: NCT02750917

Dexketoprofen and Etoricoxib in Patients Undergoing Hip Arthroplasty

Phase 4

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Dexketoprofen
Drug: Etoricoxib

First Posted Date: 2015-10-06

Last Posted Date: 2016-05-03

Lead Sponsor: Kuopio University Hospital

Target Recruit Count: 24

Registration Number: NCT02568735

Analgesic Benefit of Preoperative vs. Postoperative Etoricoxib in Total Knee Arthroplasty

Not Applicable

Completed

Conditions: Postoperative Pain

Interventions: Drug: Etoricoxib
Drug: Placebo

First Posted Date: 2015-08-27

Last Posted Date: 2015-08-27

Lead Sponsor: Foisor Orthopedics Clinical Hospital

Target Recruit Count: 165

Registration Number: NCT02534610

Locations: 🇷🇴
Foisor Orthopedics Clinical Hospital, Bucharest, Romania

Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: etoricoxib

First Posted Date: 2015-07-21

Last Posted Date: 2022-04-08

Lead Sponsor: Anne Margarita Dyrhol Riise

Target Recruit Count: 39

Registration Number: NCT02503839

Locations: 🇳🇴
Haukeland University Hospital, Bergen, Norway
🇳🇴
Oslo University Hospital, Oslo, Norway

EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).

Phase 4

Completed

Conditions: Cyclooxygenase Two Inhibitors
Etoricoxib
Periodontitis
Superoxide Dismutase
Saliva

Interventions: Drug: Etoricoxib

First Posted Date: 2014-05-29

Last Posted Date: 2014-05-29

Lead Sponsor: Tatyasaheb Kore Dental College

Target Recruit Count: 40

Registration Number: NCT02149758

Locations: 🇮🇳
Tatyasaheb kore Dental College And Research Centre, Kolhapur, Maharashtra, India

The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)

Phase 1

Completed

Conditions: Osteoarthritis Pain

Interventions: Drug: Etoricoxib 75 mg 4% DMSO Gel
Drug: Placebo
Drug: Etoricoxib 50 mg 4% DMSO
Drug: Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel
Drug: Etoricoxib 75 mg 4% PG Gel
Drug: Etoricoxib 150 mg 4% DMSO Gel
Drug: Etoricoxib 150 mg 4% PG Gel
Drug: Etoricoxib 163 mg 4% DMSO gel

First Posted Date: 2013-11-11

Last Posted Date: 2024-06-27

Lead Sponsor: Organon and Co

Target Recruit Count: 70

Registration Number: NCT01980940

Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)

Completed

Conditions: Osteoarthritis
Ankylosing Spondylitis
Gout
Arthritis
Rheumatoid Arthritis

Interventions: Drug: Etoricoxib

First Posted Date: 2012-09-14

Last Posted Date: 2022-02-18

Lead Sponsor: Organon and Co

Target Recruit Count: 79189

Registration Number: NCT01685424

Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis

Phase 3

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Drug: Celecoxib 200 mg
Drug: Etoricoxib 30 mg

First Posted Date: 2012-03-14

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 239

Registration Number: NCT01554163

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy